跳至主要内容
临床试验/NCT02665260
NCT02665260已完成2 期

Randomized Pilot Study Investigating the Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum

Montefiore Medical Center0 个研究点目标入组 94 人开始时间: 2012年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
94
主要终点
Number of Subjects Who Achieve Complete Clearance at 6 Weeks

研究概览

简要总结

The purpose of this study is to determine if cantharidin is a safe and effective treatment for molluscum contagiosum in kids

详细描述

This was a double-blind, placebo-controlled trial. Participants were recruited from the Pediatric Dermatology clinic at Montefiore Medical Center. One hundred eligible participants were randomly assigned to receive cantharidin 0.7% topical, cantharidin 0.7% topical with occlusion, placebo, or placebo with occlusion. Treatments were applied at weeks 0 and 3 (blinded phase). At week 6, all participants were treated with open-label, topical cantharidin 0.7% without occlusion every 3 weeks until all lesions resolved (open-label phase).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
2 Years 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • 2-17years
  • <50 molluscum contagiosum lesions

排除标准

  • Immunosuppressed
  • Oral corticosteroids
  • Sexually active/pregnant

研究组 & 干预措施

Cantharidin with occlusion

Active Comparator

Cantharidin 0.7% topical with occlusion

干预措施: Cantharidin (Drug)

Cantharidin with occlusion

Active Comparator

Cantharidin 0.7% topical with occlusion

干预措施: Gauze occlusion bandage (Device)

Cantharidin without occlusion

Experimental

Cantharidin 0.7% topical without occlusion

干预措施: Cantharidin (Drug)

Placebo with occlusion

Placebo Comparator

Placebo topical with occlusion

干预措施: Placebo (Drug)

Placebo with occlusion

Placebo Comparator

Placebo topical with occlusion

干预措施: Gauze occlusion bandage (Device)

Placebo without occlusion

Placebo Comparator

Placebo topical without occlusion

干预措施: Placebo (Drug)

结局指标

主要结局

Number of Subjects Who Achieve Complete Clearance at 6 Weeks

时间窗: 6 weeks

Assess number of subjects who achieve a lesion count of zero at 6 weeks (end of open-label phase)

次要结局

  • Number of Subjects Who Experienced an Adverse Event(33 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Steven R Cohen

Professor

Montefiore Medical Center

相似试验

Safety and Efficacy Study of Topical Cantharidin for... | 临床试验